Latest Us Market Expansion News

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Adveritas Limited has reported a record $14.25 million annualised recurring revenue for the December 2025 quarter, driven by strong US market growth and AI-enhanced product development. The company’s strategic focus on media agency partnerships and new product lines signals robust momentum ahead.

Ryzon Materials will exit the ASX as it pursues a US exchange listing and prepares a fresh capital raise. The company remains focused on advancing its Nachu Graphite Project despite the transition.

Ovanti Limited has completed a $1 million capital raise through a discounted share placement to accelerate its buy now, pay later business expansion in the United States.

FBR Limited has secured a binding conditional purchase order worth AUD 990,000 from a leading US heavy equipment dealer for its Mantis welding robot, marking a significant milestone during its prototyping phase.

4DMedical Limited has raised AU$150 million to accelerate the commercial rollout of its FDA-cleared CT, VQ lung imaging technology in the US, leveraging a strategic partnership with Philips. This funding aims to expand adoption across major medical centres and government healthcare programs.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.